CA2872765A1 - Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate - Google Patents

Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate Download PDF

Info

Publication number
CA2872765A1
CA2872765A1 CA2872765A CA2872765A CA2872765A1 CA 2872765 A1 CA2872765 A1 CA 2872765A1 CA 2872765 A CA2872765 A CA 2872765A CA 2872765 A CA2872765 A CA 2872765A CA 2872765 A1 CA2872765 A1 CA 2872765A1
Authority
CA
Canada
Prior art keywords
formulation
compound
range
capsule
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2872765A
Other languages
English (en)
French (fr)
Inventor
Robert Kevin Perrone
Original Assignee
Bristol Myers Squibb Holdings Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2872765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland ULC filed Critical Bristol Myers Squibb Holdings Ireland ULC
Publication of CA2872765A1 publication Critical patent/CA2872765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2872765A 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate Abandoned CA2872765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
US61/643,454 2012-05-07
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
CA2872765A1 true CA2872765A1 (en) 2013-11-14

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2872765A Abandoned CA2872765A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Country Status (33)

Country Link
US (1) US20130302414A1 (enExample)
EP (1) EP2846780B1 (enExample)
JP (1) JP6276756B2 (enExample)
KR (1) KR20150004921A (enExample)
CN (1) CN104363899A (enExample)
AR (1) AR090954A1 (enExample)
AU (1) AU2013260005B2 (enExample)
BR (1) BR112014027676A2 (enExample)
CA (1) CA2872765A1 (enExample)
CL (1) CL2014003012A1 (enExample)
CO (1) CO7141457A2 (enExample)
CY (1) CY1120756T1 (enExample)
DK (1) DK2846780T3 (enExample)
EA (1) EA028749B1 (enExample)
ES (1) ES2688817T3 (enExample)
HR (1) HRP20181583T1 (enExample)
IL (1) IL235466B (enExample)
LT (1) LT2846780T (enExample)
MX (1) MX358545B (enExample)
MY (1) MY171378A (enExample)
NZ (1) NZ630248A (enExample)
PE (1) PE20142439A1 (enExample)
PH (1) PH12014502405A1 (enExample)
PL (1) PL2846780T3 (enExample)
PT (1) PT2846780T (enExample)
RS (1) RS57881B1 (enExample)
SG (1) SG11201406964QA (enExample)
SI (1) SI2846780T1 (enExample)
SM (1) SMT201800506T1 (enExample)
TW (1) TWI577392B (enExample)
UY (1) UY34785A (enExample)
WO (1) WO2013169520A1 (enExample)
ZA (1) ZA201408967B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2673870T3 (es) * 2012-05-07 2018-06-26 Bristol-Myers Squibb Holdings Ireland Formulación de dosificación oral sólida de [(1S)-1-{[(2S,4R)-4-(7-cloro-4-metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil) carbamoil]-2-etenilciclopropil} carbamoil) pirrolidin-1-il] carbonil}-2,2-dimetil-propil] carbamato de 1,1-dimetiletilo
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
ES2298286T3 (es) * 2000-10-31 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Formulaciones de dosis orales auto-emulsionantes de inhibidores de proteasa de piranona.
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
AR090954A1 (es) 2014-12-17
HK1204552A1 (en) 2015-11-27
SMT201800506T1 (it) 2018-11-09
PL2846780T3 (pl) 2018-11-30
NZ630248A (en) 2016-11-25
UY34785A (es) 2013-11-29
AU2013260005B2 (en) 2017-07-13
MY171378A (en) 2019-10-10
HRP20181583T1 (hr) 2018-11-30
ZA201408967B (en) 2016-10-26
EA201492039A1 (ru) 2015-02-27
RS57881B1 (sr) 2019-01-31
ES2688817T3 (es) 2018-11-07
KR20150004921A (ko) 2015-01-13
CN104363899A (zh) 2015-02-18
DK2846780T3 (en) 2018-09-17
IL235466B (en) 2019-03-31
EP2846780B1 (en) 2018-07-18
LT2846780T (lt) 2018-11-12
PH12014502405A1 (en) 2015-01-12
US20130302414A1 (en) 2013-11-14
TWI577392B (zh) 2017-04-11
JP2015516418A (ja) 2015-06-11
WO2013169520A1 (en) 2013-11-14
EA028749B1 (ru) 2017-12-29
PT2846780T (pt) 2018-10-26
MX358545B (es) 2018-08-24
CY1120756T1 (el) 2019-12-11
PE20142439A1 (es) 2015-01-28
JP6276756B2 (ja) 2018-02-07
MX2014013220A (es) 2015-05-11
SI2846780T1 (sl) 2018-09-28
AU2013260005A1 (en) 2015-01-15
SG11201406964QA (en) 2014-11-27
EP2846780A1 (en) 2015-03-18
BR112014027676A2 (pt) 2017-06-27
TW201350145A (zh) 2013-12-16
CO7141457A2 (es) 2014-12-12
CL2014003012A1 (es) 2015-07-10

Similar Documents

Publication Publication Date Title
AU2013260005B2 (en) Solubilized capsule formulation of 1,1-dimethylethyl [(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US20250177320A1 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
US20130184290A1 (en) Self-emulsifying formulations and methods of use thereof
BRPI0809563A2 (pt) Formas de dosagem modificadas de tacrolimus
WO2003045357A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CN114599346A (zh) 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
CA2800279A1 (en) Oral dosage forms of bendamustine
ES2483154T3 (es) Formulaciones farmacéuticas sólidas de ramipril y besilato de amlodipino y su preparación
US20260102361A1 (en) Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
SG11202110546UA (en) Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
WO2020053658A2 (en) Non-aqueous chemotherapeutic solutions for oral dosage
WO2014002015A1 (en) Pharmaceutical composition comprising dutasteride
HK1204552B (en) Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
HK40118320A (en) Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
WO2022170398A1 (en) Formulations for improved bioavailability of fenretinide
HK40018736A (en) Pharmaceutical composition containing abiraterone acetate and preparation method and use thereof
HK40012399A (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180329

FZDE Discontinued

Effective date: 20210831